COMP <GO>
BBOT vs KROS // EV/EBITDA & P/E VALUATION
BridgeBio Oncology Therapeutics Inc. (NASDAQ) VS. Keros Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BBOT 0
— KROS 4
■ METRIC PARITY
LAST: $2.62 (-2.96%) • MKT CAP: $216.5M
valuation
—
LAST: $11.04 (-2.82%) • MKT CAP: $225.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBOT VS. KROS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BBOT | KROS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 85.00% | -120.00 | KROS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 27.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 35.70% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.31 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 8/9 | -6.00 | KROS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.1 | 40.6 | -16.52 | KROS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $216.5M | $225.2M | -$8.8M | KROS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BBOT REV | KROS REV | BBOT GROSS % | KROS GROSS % | BBOT FCF | KROS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $244.1M | — | — | -$114.5M | $106.0M |
| FY 2024 | $0 | $3.5M | — | — | -$55.1M | -$162.8M |
| FY 2023 | $0 | $151.0K | — | — | — | -$124.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBOT // BETA —
KROS // BETA —